



HAL
open science

Serum IL-6 may modulate periodontal inflammation in type 1 diabetic subjects

Anna Passoja, Matti Knuuttila, Liisa Hiltunen, Riitta Karttunen, Onni Niemelä, Taina Raunio, Olli Vainio, Pirjo Hedberg, Tellervo Tervonen

► **To cite this version:**

Anna Passoja, Matti Knuuttila, Liisa Hiltunen, Riitta Karttunen, Onni Niemelä, et al.. Serum IL-6 may modulate periodontal inflammation in type 1 diabetic subjects. *Journal of Clinical Periodontology*, 2011, 38 (8), pp.687. 10.1111/j.1600-051X.2011.01731.x . hal-00633604

HAL Id: hal-00633604

<https://hal.science/hal-00633604>

Submitted on 19 Oct 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Serum IL-6 may modulate periodontal inflammation in type 1 diabetic subjects

| | |
|-------------------------------|--|
| Journal: | <i>Journal of Clinical Periodontology</i> |
| Manuscript ID: | CPE-11-10-2960.R2 |
| Manuscript Type: | Original Article Clinical Periodontology |
| Date Submitted by the Author: | 16-Mar-2011 |
| Complete List of Authors: | Passoja, Anna; Finnish Doctoral Program in Oral Sciences Knuuttila, Matti; Institute of Dentistry, Department of Periodontology and Geriatric Dentistry, University of Oulu; Oulu University Hospital, Oral and Maxillofacial Department Hiltunen, Liisa; Health Centre of Oulu; Vaasa Central Hospital, Department of Primary Health Care Karttunen, Riitta; Helsinki University Central Hospital, Department of Bacteriology and Immunology, Laboratory Division (HUSLAB); Institute of Diagnostics, Department of Medical Microbiology, University of Oulu Niemelä, Onni; Seinäjoki Central Hospital and University of Tampere, Medical Research Unit Raunio, Taina; Specialist Dental Health Care Unit, City of Oulu Vainio, Olli; University of Oulu, Institute of Diagnostics, Department of Medical Microbiology and Immunology,; Oulu University Hospital, Clinical Microbiology Laboratory Hedberg, Pirjo; Oulu University Hospital, Laboratory, Department of Clinical Chemistry Tervonen, Tellervo; Institute of Dentistry, University of Oulu, Department of Periodontology and Geriatric Dentistry; Oulu University Hospital, Oral and maxillofacial Department |
| Topic: | Aetiology |
| Keywords: | Periodontal disease, Gingivitis, periodontal pocket, periodontitis |
| Main Methodology: | Biochemistry |
| | |

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11 **Serum interleukin-6 may modulate periodontal inflammation in type 1 diabetic subjects**
12
13
14
15
16
17
18

19 **Passoja A^{1,2}, Knuuttila M^{1,3}, Hiltunen L^{4,5}, Karttunen R^{6,7}, Niemelä O⁸, Raunio T⁹, Vainio**
20
21 **O^{7,10}, Hedberg P^{11,12}, Tervonen T^{1,3}**
22
23
24
25

26 ¹Department of Periodontology and Geriatric Dentistry, University of Oulu, Oulu, Finland,
27 ²Finnish Doctoral Program in Oral Sciences, Oulu, Finland, ³Oral and Maxillofacial Department,
28 Oulu University Hospital, Oulu, Finland, ⁴Health Centre of Oulu, Oulu, Finland, ⁵Vaasa Central
29 Hospital, Department of Primary Health Care, Vaasa, Finland, ⁶Department of Bacteriology and
30 Immunology, Haartman Institute, Laboratory Division (HUSLAB), Helsinki University Central
31 Hospital, University of Helsinki, Helsinki, Finland, ⁷Institute of Diagnostics, Department of
32 Medical Microbiology and Immunology, University of Oulu, Oulu, Finland, ⁸Medical Research
33 Unit, Seinäjoki Central Hospital and University of Tampere, Finland, ⁹Specialist Dental Health
34 Care Unit, City of Oulu, Oulu, Finland, ¹⁰Clinical Microbiology Laboratory, Oulu University
35 Hospital, Oulu, Finland, ¹¹Laboratory, Oulu University Hospital, Oulu, Finland, ¹²Institute of
36 Diagnostics, Department of Clinical Chemistry, University of Oulu, Oulu, Finland
37
38
39
40
41
42

43 Short title: Serum IL-6 and periodontal inflammation
44

45 Key words: bleeding on probing, inflammation, interleukin (IL)-6, periodontitis, diabetes mellitus,
46 serum
47
48
49

50 Corresponding author: TTervonen, Box 5281, 90014 University of Oulu, Finland
51

52 e-mail: tellervo.tervonen@oulu.fi
53
54
55
56
57
58
59
60

1
2
3 Passoja A, Knuuttila M, Hiltunen L, Karttunen R, Niemelä O, Raunio T, Vainio O, Hedberg P,
4 Tervonen T. Serum IL-6 may modulate periodontal inflammation in type 1 diabetic subjects.
5
6

7 Journal of Clinical Periodontology
8

9 **Abstract**
10

11 **Aims:** To evaluate associations between serum inflammatory biomarkers and periodontal
12 inflammation in subjects with type 1 diabetes mellitus (T1DM). Our hypothesis was that local host
13 responses may be modulated by the serum inflammatory mediators.
14
15
16
17

18 **Material and methods:** Plaque, bleeding on probing (BOP) and probing pocket depth (PD) were
19 examined in 80 T1DM subjects at the baseline and in 58 subjects 8 weeks after periodontal therapy.
20
21 The levels of glycosylated haemoglobin (HbA1c), serum interleukin (IL)-6, ultrasensitive C-
22 reactive protein (usCRP) and the lipid profile were measured at the baseline and after therapy.
23
24 Stratification of the sample separately by smoking and body mass index (BMI) was performed.
25
26 Adjusted associations between the levels of systemic biomarkers and periodontal parameters were
27 studied using multiple regression models.
28
29
30
31
32
33
34

35 **Results:** The level of serum IL-6 was associated with the extent of bleeding and $PD \geq 4$ mm at the
36 baseline in non-smokers and in subjects with $BMI \leq 26$ kg m⁻². These associations were also
37 evident after periodontal therapy. Subjects with a high after-therapy IL-6 level presented poorer
38 periodontal healing than those with a low level.
39
40
41
42
43
44

45 **Conclusions:** The observed associations may be regarded suggestive of a modulatory effect of IL-6
46 on host responses in T1DM subjects.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Conflict of interest and source of funding statement:**
4

5
6 The authors declare that they have no conflicts of interest.
7

8
9 The study was self-funded by the authors and their institutions.
10

11
12
13 **Clinical Relevance**
14

15
16 *Scientific rationale for the study*
17

18 While some studies indicate a causative role of periodontal infection on systemic inflammatory
19 responses, less is known of the influence of high serum levels of pro-inflammatory mediators on
20 local host responses.
21
22
23
24

25
26
27
28 *Principal findings*
29

30 The level of serum IL-6 was associated with the extent of bleeding and PD \geq 4 mm at the baseline
31 in non-smokers and in subjects with BMI \leq 26 kg m⁻². These associations were also evident after
32 periodontal therapy. Subjects with a high IL-6 level presented poorer periodontal healing than
33 those with a low level.
34
35
36
37
38

39
40
41
42 *Practical implications*
43

44 Serum IL-6 may modulate inflammatory responses in the periodontal area and contribute to both
45 the progression and healing of periodontal inflammation as it contributes to the initiation and
46 progression of other inflammation-associated diabetic complications.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Hyperglycemia is known to evoke a pro-inflammatory state characterised by increased concentrations of systemic inflammatory biomarkers such as cell adhesion molecules, C-reactive protein (CRP) and pro-inflammatory cytokines, including interleukin (IL)-6 and tumour necrosis factor (TNF)- α (Devaraj et al. 2007, Kaul et al. 2010). While it is generally accepted that the major causative factor behind diabetic complications is hyperglycemia, growing evidence exists that the development and progression of diabetic micro- and macro-vascular complications are also linked with systemic inflammation (Saraheimo et al. 2003, Devaraj et al. 2007). Both gingivitis and periodontitis have been considered as hyperglycemia-related diabetic complications (Taylor 2001, Lalla et al 2007a). Since the very first reports by Gislen and co-workers (1980) and by our own group (Ervasti et al. 1985, Tervonen & Knuutila 1986), the role of the metabolic control of diabetes mellitus as the main determinant of increased periodontal inflammation has been confirmed in a large number of studies (Taylor 2001, Lalla et al 2007a). Importantly, both micro-vascular complications and periodontal inflammation seem to share at least some potential hyperglycemia-related pathways in their development, including hyperglycemia-enhanced formation of advanced glycation end products (AGEs), protein kinase C activation, increased oxidative stress and apoptosis (Graves et al. 2006, Devaraj et al. 2007, Nassar et al. 2007, van den Oever 2010).

It is nowadays generally agreed that chronic periodontitis is associated with low-grade systemic inflammation both in non-diabetic (Loos 2005, Nibali et al. 2007, Saxlin et al. 2009) and in diabetic (Engebretson et al. 2007, Lim et al. 2007, Chen et al. 2010) individuals. On the contrary, less is known about the contribution of elevated levels of serum inflammatory mediators to periodontal inflammation. This biological pathway was recently studied by Andriankaja and co-workers (2009), who observed a significant association between serum IL-6 and gingivitis in type 2 diabetic subjects with no deepened periodontal pockets (≥ 3 mm) and bleeding on probing $\geq 10\%$. One of the

1
2
3 conclusions drawn by the authors was that serum IL-6 might have a specific role in modulating
4
5 local inflammatory reaction in individuals with type 2 diabetes.
6
7

8 We determined the periodontal health status and systemic inflammation in a group of T1DM
9
10 subjects before and after periodontal therapy to explore the possible bidirectional nature of the
11
12 association between periodontal health and systemic inflammatory status. Moreover, our aim was to
13
14 study whether the possible link between periodontal and systemic inflammation is analogous to the
15
16 link between systemic inflammation and the development and progression of micro-vascular
17
18 complications of diabetes mellitus.
19
20
21

22 23 24 **Material and Methods**

25
26 The study protocol was approved by the Ethical Committee of Oulu University Hospital, Oulu,
27
28 Finland, and an informed consent form was signed by the subjects.
29
30

31 32 **Subjects**

33
34 Originally, a total of 80 patients with T1DM were recruited on a volunteer basis and examined
35
36 clinically by a periodontal specialist (T.R.) at the Specialist Dental Health Care Unit, City of Oulu,
37
38 Finland (Tervonen et al 2009). Subjects needing prophylactic antibiotic medication in association
39
40 with periodontal probing and those with immunosuppressive medication or antibiotics during the
41
42 past four months were excluded. After anti-infective periodontal therapy a total of 65 subjects were
43
44 re-examined. Data on glycosylated haemoglobin (HbA1c), high-density HDL cholesterol, low-
45
46 density LDL cholesterol, IL-6 and usCRP were available for all subjects at the baseline and for 59
47
48 subjects after therapy. One subject with a severe and acute wound infection and maxillary sinusitis
49
50 presented a pronounced increase in serum IL-6 (from 3.6 pg/ml to 8.2 pg/ml) during the study and
51
52 was excluded, leaving a total of 58 treated subjects for the analyses.
53
54
55

56
57 Patient records were used to retrieve data regarding the general health status of the subjects. Four
58
59 subjects had either chronic maxillary sinusitis, skin infection or symptoms of a urinary tract
60

1
2
3 infection during the study (indicated in Fig. 1A). Smoking data were obtained by an interview and
4
5 the subjects were categorised as smokers and non-smokers. A total of 56 subjects of those examined
6
7 at the baseline and 44 out of the treated subjects reported to be non-smokers. The subjects' body
8
9 mass index (BMI kg m⁻²) and age were also recorded. A total of 58 subjects out of those studied at
10
11 the baseline and 44 of the treated subjects had BMI ≤ 26 kg m⁻² (Table 1) (according to the WHO,
12
13 the lower limit for overweight is 25 kg m⁻²).
14
15

17 **Clinical periodontal examination and periodontal therapy**

18
19 Periodontal variables were recorded on mesiobuccal, midbuccal, distobuccal and midlingual
20
21 surfaces of each tooth as described earlier (Tervonen et al. 2009). Shortly, the presence of visible
22
23 plaque according to the criteria of the scores 2 and 3 of the plaque index (Silness & L oe 1964),
24
25 probing depth (PD) and bleeding on probing (BOP) were registered. Anti-infective periodontal
26
27 therapy including oral hygiene education, scaling and root planing were performed. As the goal was
28
29 to minimise periodontal inflammation, these treatments were repeated and periodontal surgery was
30
31 performed whenever indicated. In the follow-up examination approximately 8 weeks after the
32
33 completion of the treatment 1-9 bleeding sites were found in 14 subjects, 10-19 sites in 19 and > 20
34
35 sites in 16 subjects. Moreover, bleeding and PD ≥ 4 mm were detected at 1-2 sites in 14 subjects
36
37 and at 3-10 sites in 7 subjects.
38
39
40
41
42

43 **Laboratory assays**

44
45 Venous blood samples were drawn at the baseline and in the follow-up examination. Glycosylated
46
47 haemoglobin (HbA1c, %) was analysed using a latex immunoturbidimetric method (Siemens
48
49 Medical Solutions Diagnostics, Tarrytown, NY 10591-5097 USA). Serum samples were stored at -
50
51 70 °C until assayed. Serum IL-6 level (pg/ml) was measured with a sensitive ELISA Quantikine HS
52
53 Immunoassay kit (R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany). The usCRP
54
55 (ultrasensitive CRP, mg/l) analyses were made using an Innotrac Aio! analyser (Innotrac
56
57 Diagnostics Oy, Turku, Finland), that utilises a unique all-in-one (Aio!) dry-reagent concept and
58
59
60

1
2
3 time-resolved fluorometric detection (Hedberg et al. 2004). Low-density LDL cholesterol (mmol/l)
4
5 and high-density HDL cholesterol (mmol/l) were measured using direct enzymatic methods
6
7 implemented in the Advia 2400 Chemistry systems (Siemens Medical Solutions Diagnostics,
8
9 Tarrytown, NY 10591-5097 USA).

10
11
12 An 'increase' in IL-6 level between the baseline and the follow-up examination was recorded if the
13
14 level was elevated by ≥ 0.2 pg/ml, a 'decrease' if the level dropped by ≥ 0.2 pg/ml and a lack of
15
16 either of the previous was considered a 'stable' level (Fig. 1A).

17 18 19 20 **Statistical methods**

21
22 Statistical analyses were performed using statistical software (SPSS Statistical Package for Social
23
24 Sciences, version 16.0 for Windows; SPSS Inc., Chicago, IL, USA) and the level of statistical
25
26 significance was set at $< 5\%$ ($p < 0.05$). All analyses were based on subject-level data. The extent of
27
28 periodontal inflammation was measured as the number of affected sites per subject. Mean serum IL-
29
30 6 level before and after therapy were compared using the Wilcoxon signed ranks test. Spearman's
31
32 rank correlation analysis was used to study unadjusted associations between periodontal parameters
33
34 and serum inflammatory markers at the baseline (Table 2). Depending on the distribution of the
35
36 outcome, variable-adjusted associations between periodontal inflammation and serum inflammatory
37
38 markers were studied using either linear regression or binomial regression analyses. In the binomial
39
40 regression models the \ln of the number of measured sites was used as an offset variable. In order to
41
42 control the confounding/modifying effect of smoking and BMI on the association between serum
43
44 IL-6 and periodontal inflammation, we used the interaction terms BMI*IL-6 and smoking*IL-6 in
45
46 the models. We also stratified the sample by BMI (≤ 26 kg m⁻² / > 26 kg m⁻²) and smoking (non-
47
48 smokers / smokers) to study the associations in the stratified samples. The association between
49
50 periodontal healing and serum IL-6 level was studied using linear regression analysis with the
51
52 reduction in the number of sites with bleeding and PD ≥ 4 mm (number of sites after therapy
53
54 deducted from the number of sites at the baseline, range -2 - 90) as the outcome.
55
56
57
58
59
60

Results

The subject characteristics are presented in Table 1. The group of treated subjects was comparable with the whole study group in terms of age, gender, smoking habits, BMI, duration of DM and number of teeth. Regardless of a favorable response to periodontal therapy, no essential changes in the mean levels of serum inflammatory markers from the baseline to the follow-up examination could be observed.

Based on the unadjusted associations between serum inflammatory markers and the periodontal parameters at the baseline (Table 2), we studied the adjusted associations between the number of sites with BOP and bleeding and $PD \geq 4$ mm (the outcome variables) and serum IL-6 and HbA1c in further analyses using multiple regression models. The regression analyses of all subjects both at the baseline and after periodontal therapy (non-stratified samples) revealed statistically significant associations between serum IL-6 and periodontal inflammation. We then controlled for possible interaction between serum IL-6 and smoking and serum IL-6 and BMI by adding the interaction term smoking*IL-6 and BMI*IL-6 into the model and found that the interaction terms were not statistically significant in the models. Neither was there any statistically significant association between serum IL-6 level and periodontal inflammation in the new model (data not shown). Therefore, further analyses were done in samples stratified separately by smoking and BMI. While serum HbA1c level was associated significantly with BOP and bleeding and $PD \geq 4$ mm both in subjects with $BMI \leq 26$ kg m⁻² and in non-smokers at the baseline, serum IL-6 level turned out to be a statistically significant determinant of the number of sites with bleeding and $PD \geq 4$ mm in the same subjects (Table 3, *Models I and II*). At the baseline, the adjusted associations between serum IL-6 level and the number of sites with BOP and bleeding and $PD \geq 4$ mm were not statistically significant in subjects with $BMI > 26$ kg m⁻² (n = 22) and in smokers (n = 24) (data not shown).

1
2
3 After periodontal therapy, a statistically significant association was found between the level of
4 serum IL-6 and the number of sites with bleeding and $PD \geq 4$ mm in subjects with $BMI \leq 26 \text{ kg m}^{-2}$
5
6
7
8 ($p = 0.043$) (Table 4, *Model III*). In non-smokers this association was of borderline significance ($p =$
9
10 0.064) (Table 4, *Model IV*). The number of sites with bleeding and $PD \geq 4$ mm after therapy was
11
12 not associated with smoking. The actual serum levels of IL-6 in subjects with $BMI \leq 26 \text{ kg m}^{-2}$ and
13
14 in non-smokers according to the number of residual sites with bleeding and $PD \geq 4$ mm after
15
16 periodontal therapy are presented in Table 5. These results also indicate that the level of serum IL-6
17
18 is higher in subjects with higher numbers of residual sites with inflammation. The adjusted
19
20 associations between serum IL-6 level and the number of sites with BOP and bleeding and $PD \geq 4$
21
22 mm were not statistically significant in subjects with $BMI > 26 \text{ kg m}^{-2}$ ($n = 14$) and in smokers ($n =$
23
24 14) after therapy (data not shown).
25
26
27
28

29 A decrease (≥ 0.2 pg/ml) in serum IL-6 level was observed in 23 (39.7%) subjects between the
30
31 baseline and the follow-up examination. The level remained stable in 18 (31.0%) subjects and an
32
33 increase (≥ 0.2 pg/ml) was observed in 17 (29.3%) subjects (Fig. 1A). Subjects with chronic
34
35 infections were evenly distributed into the previous groups (Fig. 1A). The reduction in the number
36
37 of sites with bleeding and $PD \geq 4$ mm, was similar in subjects with a decreased, stable or increased
38
39 serum IL-6 level (Fig. 1 B). After controlling for confounding factors a statistically significant
40
41 association ($p = 0.003$) was found between periodontal healing (the outcome variable) and the after-
42
43 therapy serum IL-6 level, indicating poorer periodontal healing in subjects with a high IL-6 level
44
45 (Table 6). In a second model (data not shown) including the interaction terms $BMI*IL-6$ and
46
47 $smoking*IL-6$ the above association turned out to be weaker ($p=0.022$). The interaction terms were,
48
49 however, not statistically significant.
50
51
52
53
54
55
56
57
58
59
60

Discussion

In line with earlier studies (Loos et al. 2000, Buhlin et al. 2003) reporting higher serum IL-6 levels in patients with chronic periodontitis than in healthy control subjects, we found a statistically significant association between the level of serum IL-6 and the number of sites with bleeding and PD \geq 4 mm at the baseline. A new finding was that this association was evident also after periodontal therapy. We also observed that periodontal therapy was not consistently followed by a decrease in serum IL-6 level and that periodontal healing turned out to be poorer in subjects with a high after-therapy IL-6 level than in those with a low level.

When interpreting the above observations, we started from the premise that the causal pathway between serum IL-6 and periodontal inflammation may be bidirectional. Increased serum levels of inflammatory markers, such as IL-6, in subjects with chronic periodontitis have been explained by dumping of locally concentrated IL-6 from the inflamed areas into the circulation, its production by distant immune cells as a response to bacterial irritation from the site of infection or both. In light of the above, a high serum IL-6 level observed at the baseline of this study may be interpreted as reflecting a high extent of periodontal inflammation.

The association between serum IL-6 level and the number of sites with bleeding and PD \geq 4mm after therapy on one hand, and the reduction in the number of sites with bleeding and PD \geq 4mm on the other hand, was interpreted to indicate poorer periodontal healing in subjects with higher serum IL-6 levels and to be suggestive of a causal pathway, where a high serum IL-6 level acts as a susceptibility factor for periodontal inflammation. IL-6 is known for its pro-inflammatory properties (Kaplanski et al. 2003, Gabay 2006, Kishimoto 2006) and it also accelerates bone resorption (Tamura et al. 1993). Therefore, a high serum IL-6 level may boost inflammation and modulate tissue responses locally in the periodontal area. Although we consider the above direction of the causal pathway more likely, one could also speculate that the resolution of inflammation

1
2
3 contributed to the decreased serum IL-6 levels; the higher the number of healed sites, the less IL-6
4
5 could be detected in serum after therapy. Supporting this, slightly decreased levels of serum
6
7 inflammatory markers after anti-infective therapies have been reported (D'Aiuto et al. 2004, 2005,
8
9 Kardeşler et al. 2010). However, in our subjects, the decrease in the mean serum IL-6 level from the
10
11 baseline to the follow-up examination (0.1 pg/ml) was not statistically significant. In addition,
12
13 similar periodontal healing was followed by a decrease in IL-6 level in 40%, a stable level in 31%
14
15 and an increase in 29% of the subjects (Figs. 1A,B). These results further support our interpretation
16
17 that serum IL-6 acts as a susceptibility factor for periodontal inflammation. We can't fully exclude
18
19 that there were also other mechanisms/conditions, such as sub-clinical or unreported infections,
20
21 which may have contributed to the serum IL-6 levels. Also, including a non-diabetic group with a
22
23 comparable periodontal health status would have made it possible to assess the influence of diabetes
24
25 mellitus itself on the systemic IL-6.
26
27

28
29 One of the methodological challenges in studies of the periodontal-systemic relationship is to
30
31 adequately control the confounding/modifying effects of smoking and BMI. Smoking is known to
32
33 deteriorate periodontal health (Bergström 2006) and evidently increase the serum IL-6 level (Tappia
34
35 et al. 1995). On the other hand, adipose tissue is considered an important source of IL-6 (Mohamed-
36
37 Ali et al. 1997, Fried et al. 1998), and obesity/BMI has been associated with chronic periodontitis
38
39 (Ylöstalo et al. 2008). We took into consideration the above both by using respective interaction
40
41 terms in the multivariate models and by stratifying the samples according to smoking and BMI. Due
42
43 to the small sample size, stratification according to smoking and BMI at the same time was not
44
45 possible. As regards a more complete control of the confounding/modifying effect of smoking and
46
47 BMI, a need for verification of our result in larger samples remains. Moreover, a more definite
48
49 measure of smoking, such as pack-years, should be used.
50
51

52
53 As the goal of periodontal therapy was to minimise periodontal inflammation, anti-infective
54
55 treatments were continued until this goal was reached. The lack of a statistically significant
56
57
58
59
60

1
2
3 association between smoking and periodontal inflammation after therapy can be explained by the
4 setting of the study where additional treatments were delivered to poorly responding subjects such
5 as smokers. Considering the treatment protocol used and the suggested poorer healing response of
6 subjects with higher IL-6 levels, we speculate that the strength of the association between serum IL-
7 6 and the number of inflamed sites after therapy was underestimated.
8
9

10
11
12
13
14
15 The shortcomings of this study include the fairly small sample size and lack of power analysis for
16 the sample size. Moreover, this study allows us to suggest a bidirectional relationship between
17 serum IL-6 level and periodontal inflammation exclusively in T1DM subjects. Regarding the
18 observed association between serum IL-6 level and periodontal inflammation, the chance of a
19 spurious association must also be considered; in that case there are one or more common
20 background factors contributing to both the increased serum level and the higher extent of
21 periodontal inflammation.
22
23
24
25
26
27
28
29
30

31
32 In summary, while serum IL-6 level was associated significantly with periodontal inflammation at
33 the baseline, resolution of inflammation was not followed by a decrease in the serum IL-6 level in
34 all subjects. The response to anti-infective periodontal therapy was poorer in subjects with a high
35 after-therapy level of serum IL-6 than in those with a low level. Thus, a high serum IL-6 level may
36 modulate inflammatory responses in the periodontal area as it modulates the development and
37 progression of diabetic micro- and macro-vascular complications. The evident bidirectional causal
38 pathway between serum IL-6 and periodontal inflammation is essential in elucidating both the
39 pathogenesis of periodontitis and periodontal-systemic relationships. Therefore future studies
40 should be focused on confirming the observed associations also in non-diabetic individuals.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

Andriankaja, O. M., Barros, S. P., Moss, K., Panagakos, F. S., DeVizio, W., Beck, J. & Offenbacher, S. (2009) Levels of serum interleukin (IL)-6 and gingival crevicular fluid of IL-1beta and prostaglandin E(2) among non-smoking subjects with gingivitis and type 2 diabetes. *Journal of Periodontology* **80**, 307–316.

Bergström, J. (2006) Periodontitis and smoking. *Journal of Evidence Based Dental Practice* **6**, 33-41.

Buhlin, K., Gustafsson, A., Pockley, A.G., Frostegård, J., Klinge, B. (2003) Risk factors for cardiovascular disease in patients with periodontitis. *European Heart Journal* **24**, 2099-2107.

Chen, L., Wei, B., Li, J., Liu, F., Xuan, D., Xie, B. & Zhang, J. (2010) Association of periodontal parameters with metabolic level and systemic inflammatory markers in patients with type 2 diabetes. *Journal of Periodontology* **81**, 364–371.

D’Aiuto, F., Parkar, M., Andreaou, G., Brett, P. M., Ready, D. & Tonetti, M. S. (2004) Periodontitis and atherogenesis: causal association or simple coincidence? *Journal of Clinical Periodontology* **31**, 402–411.

D’Aiuto, F., Nibali, L., Parkar, M., Suvan, J. & Tonetti, M. S. (2005) Short-term effects of intensive periodontal therapy on serum inflammatory markers and cholesterol. *Journal of Dental Research* **84**, 269–273.

Devaraj, S., Cheung, A. T., Jialal, I., Griffen, S. C., Nguyen, D., Glaser, N. & Aoki, T. (2007) Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. *Diabetes* **56**, 2790–2796.

Engbretson, S., Chertog, R., Nichols, A., Hey-Hadavi, J., Celenti, R., Grbic, J. (2007) Plasma levels of tumour necrosis factor- α in patients with chronic periodontitis and type 2 diabetes. *Journal of Clinical Periodontology* **34**, 18-24.

1
2
3 Ervasti, T., Pohjamo, L., Haukipuro, K. & Knuuttila, M. (1985) Relation between control of
4 diabetes and gingival bleeding. *Journal of Periodontology* **56**, 154–157.

5
6
7
8 Fried, S. K., Bunkin, D. A. & Greenberg, A. S. (1998) Omental and subcutaneous adipose tissues of
9 obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. *Journal of*
10 *Clinical Endocrinology and Metabolism* **83**, 847–850.

11
12
13
14
15 Gabay, C. (2006) Interleukin-6 and chronic inflammation. *Arthritis Research & Therapy* **8 Suppl 2**,
16 S3.

17
18
19
20
21 Gislén, G., Nilsson, K. & Mattson, L. (1980) Gingival inflammation in diabetic children related to
22 degree of metabolic control. *Acta Odontologica Scandinavica* **38**, 241–246.

23
24
25
26
27 Graves, D. T., Liu, R., Alikhani, M., Al-Mashat, H. & Trackman, P. C. (2006) Diabetes-enhanced
28 inflammation and apoptosis – impact on periodontal pathology. *Journal of Dental Research* **85**, 15–
29 21.

30
31
32
33
34 Hedberg, P., Ylitalo, K. & Puukka, M. (2004) Highly sensitive determination of C-reactive protein
35 on the Innotracs Aio! immunoanalyzer. *Scandinavian Journal of Clinical and Laboratory*
36 *Investigation* **64**, 677–686.

37
38
39
40
41 Kaplanski, G., Marin, V., Montero-Julian, F., Mantovani, A. & Farnarier, C. (2003) IL-6: a
42 regulator of the transition from neutrophil to monocyte recruitment during inflammation. *Trends in*
43 *Immunology* **24**, 25-29.

44
45
46
47
48 Kardeşler, L., Buduneli, N., Cetinkalp, S. & Kinane, D. F. (2010) Adipokines and inflammatory
49 mediators after initial periodontal treatment in patients with type 2 diabetes and chronic
50 periodontitis. *Journal of Periodontology* **81**, 24-33.

51
52
53
54
55 Kaul, K., Hodkinson, A., Tarr, J., Koehner, E. M. & Chibber, R. (2010) Is inflammation a common
56 retinal-renal-nerve pathogenic link in diabetes? *Current Diabetes Reviews*, **6**, 294-303.

57
58
59
60 Kishimoto, T. (2006) Interleukin-6: discovery of a pleiotypic cytokine. *Arthritis Research &*
Therapy **8 Suppl 2**, S2.

1
2
3
4
5 Lalla, E., Cheng, B., Lal, S., Kaplan, S., Softness, B., Greenberg, E., Goland, R. S. & Lamster, I. B.
6 (2007a) Diabetes mellitus promotes periodontal destruction in children. *Journal of Clinical*
7 *Periodontology* **34**, 294–298.
8
9

10
11
12 Lim, L. P., Tay, F. B. K., Sum, C. F. & Thai, A. C. (2007) Relationship between markers of
13 metabolic control and inflammation on severity of periodontal disease in patients with diabetes
14 mellitus. *Journal of Clinical Periodontology* **43**, 118–123.
15
16
17

18
19
20 Loos, B. G., Craandijk, J., Hoek, F. J., Wertheim-van Dillen, P. M. E. & van der Velden, U. (2000)
21 Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of
22 periodontitis patients. *Journal of Periodontology* **71**, 1528–1534.
23
24
25

26
27 Loos, B. G. (2005) Systemic markers of inflammation in periodontitis. *Journal of Periodontology*
28 **76**, 2106–2115.
29
30

31
32 Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D. R., Miles, J. M., Yudkin, J. S., Klein, S. &
33 Coppack, S. W. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis-
34 α , in vivo. *Journal of Clinical Endocrinology and Metabolism* **82**, 4196–4200.
35
36
37

38
39 Nassar, H., Kantarci, A. & VanDyke, T. (2007) Diabetic periodontitis: a model for activated innate
40 immunity and impaired resolution of inflammation. *Periodontology 2000* **43**, 233–244.
41
42
43

44
45
46 Nibali, L., D'Aiuto, F., Griffiths, G., Patel, K., Suvan, J., Tonetti, M.S. (2007) Severe periodontitis
47 is associated with systemic inflammation and a dysmetabolic status: a case-control study. *Journal of*
48 *Clinical Periodontology* **34**, 931–937.
49
50
51

52
53
54
55
56
57 Saxlin, T., Suominen-Taipale, L., Leiviskä, J., Jula, A., Knuutila, M. & Ylöstalo, P. (2009) Role of
58 serum cytokines tumour necrosis factor-alpha and interleukin-6 in the association between body
59 weight and periodontal infection. *Journal of Clinical Periodontology* **36**, 100–105.
60

1
2
3
4 Saraheimo, M., Teppo, A.M., Forsblom, C., Fagerudd, J., Groop, P.H. (2003) Diabetic nephropathy
5 is associated with low-grade inflammation in Type 1 diabetics. *Diabetologia* **46**, 1402-1407.
6
7

8
9 Silness, J. & Løe, H. (1964) Periodontal disease in pregnancy (II). Correlation between oral hygiene
10 and periodontal condition. *Acta odontologica scandinavica* **24**, 747-759.
11
12

13
14 Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., Koishihara, Y.,
15 Ohsugi, Y., Kumaki, K., Taga, T., Kishimoto, T. & Suda, T. (1993) Soluble interleukin-6 reseptor
16 triggers osteoclast formation by interleukin-6. *Proceedings of the National Academy of Science of*
17 *the USA* **90**, 11924-11928.
18
19
20
21

22
23 Tappia, P.S., Troughton, K.L., Langley-Evans, S.C., Grimble, R.F. (1995) Cigarette smoking
24 influences cytokine production and antioxidant defences. *Clinical Science* **88**, 485-489.
25
26
27

28
29 Taylor, G.W. (2001) Bidirectional interrelationships between diabetes and periodontal diseases: an
30 epidemiologic perspective. *Annals of Periodontology* **6**: 99-112.
31
32

33
34 Tervonen, T. & Knuuttila, M. (1986) Relation of diabetes control to periodontal pocketing and
35 alveolar bone level. *Oral Surgery Oral Medicine Oral Pathology* **61**, 346-9.
36
37

38
39 Tervonen, T., Lamminsalo, S., Hiltunen, L., Raunio, T. & Knuuttila, M. (2009) Resolution of
40 periodontal inflammation does not guarantee improved glycemic control in type 1 diabetic subjects.
41 *Journal of Clinical Periodontology* **36**, 51-57.
42
43
44

45
46 van den Oever, I. A. M., Raterman, H. G., Nurmohamed, M. T. & Simsek, S. (2010) Endothelial
47 dysfunction, inflammation, and apoptosis in diabetes mellitus. *Mediators of Inflammation*
48 doi:10.1155/2010/792393.
49
50
51

52
53 Ylöstalo, P., Suominen-Taipale, L., Reunanen, A., Knuuttila, M. (2008) Association between body
54 weight and periodontal infection. *Journal of Clinical Periodontology* **35**, 297-304.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 1. Subject characteristics presented as mean values/subject (± SD) and numbers of subjects.

| | Baseline | | After therapy |
|--------------------------------|-----------------------|---------------------------|---------------|
| | All subjects (n = 80) | Treated subjects (n = 58) | (n = 58) |
| Age, years | 38.6 ± 12.3 | 39.5 ± 12.6 | 39.5 ± 12.6 |
| Gender (female/male) | 46/34 | 34/24 | 34/24 |
| Smoking (non-smoker/smoker) | 56/24 | 44/14 | 44/14 |
| BMI ≤ 26 (kg m ⁻²) | 58/22 | 44/14 | 44/14 |
| Duration of DM, years | 19.9 ± 11.9 | 20.1 ± 10.8 | 20.1 ± 10.8 |
| Number of | | | |
| Teeth | 25.7 ± 4.1 | 26.2 ± 3.2 | 26.0 ± 3.3 |
| Sites | 102.9 ± 16.5 | 105.0 ± 12.8 | 103.8 ± 13.1 |
| Number of sites with | | | |
| Plaque | 30.7 ± 22.3 | 30.1 ± 21.8 | 3.4 ± 8.2 |
| BOP | 69.3 ± 18.1 | 70.9 ± 15.1 | 14.9 ± 12.9 |
| Bleeding and PD ≥ 4 mm | 23.1 ± 18.5 | 23.0 ± 19.0 | 1.0 ± 2.1 |
| IL-6 (pg/ml) | 1.7 ± 1.0 | 1.7 ± 1.0 | 1.6 ± 1.1 |
| HbA1c (%) | 8.5 ± 1.4 | 8.5 ± 1.4 | 8.4 ± 1.4 |
| HDL (mmol/l) | 1.6 ± 0.4 | 1.5 ± 0.4 | 1.5 ± 0.3 |
| LDL (mmol/l) | 2.3 ± 0.8 | 2.4 ± 0.7 | 2.4 ± 0.7 |
| usCRP (mg/l) | 2.3 ± 3.9 | 2.3 ± 3.9 | 2.9 ± 4.8 |
| BMI (kg m ⁻²) | 24.7 ± 3.3 | 24.5 ± 3.1 | 24.5 ± 3.1 |

BOP, bleeding on probing; bleeding and PD ≥ 4mm, bleeding pocket ≥ 4mm in depth ; HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; usCRP, ultrasensitive C-reactive protein; BMI, body mass index

Table 2. Unadjusted associations, based on Spearman's rank correlation analysis, between the numbers of sites presenting bleeding on probing (BOP) and bleeding and PD \geq 4 mm, serum inflammatory markers and body mass index (BMI) at the baseline.

| | BOP | Bleeding PD \geq 4 mm | HbA1c | IL-6 | HDL | LDL | usCRP |
|-------------------------|-----------------------------------|------------------------------|------------------------------|-----------------------------------|------------------------------|------------------------------|------------------------------|
| Bleeding PD \geq 4 mm | 0.715 < 0.001 | | | | | | |
| HbA1c | 0.332 0.003 | 0.258 0.021 | | | | | |
| IL-6 | 0.137 0.226 | 0.234 0.037 | 0.071 0.534 | | | | |
| HDL | -0.128 0.257 | -0.219 0.051 | 0.025 0.823 | -0.127 0.260 | | | |
| LDL | 0.142 0.210 | 0.049 0.669 | 0.136 0.231 | 0.148 0.191 | 0.322 0.004 | | |
| usCRP | 0.156 0.167 | 0.140 0.215 | 0.348 0.002 | 0.427 < 0.001 | 0.223 0.047 | 0.279 0.012 | |
| BMI | 0.045 0.692 | 0.028 0.808 | -0.045 0.694 | 0.187 0.097 | -0.031 0.787 | 0.293 0.008 | 0.272 0.015 |

Correlation coefficients, p-values; statistically significant values are presented in boldface.

Table 3. Adjusted associations between the number of bleeding sites (BOP) and sites with bleeding and PD \geq 4 mm (the outcome variables) and serum IL-6 level at the baseline in subjects with BMI \leq 26 kg m⁻² and in non-smokers.

| | B | 95% CI | p-value |
|---|---------------|------------------------|--------------|
| Model I; BMI \leq 26 kg m⁻² (n = 58) | | | |
| BOP* | | | |
| IL-6 | 3.029 | -0.553-6.612 | 0.096 |
| HbA1c | 4.032 | 1.515-6.549 | 0.002 |
| Smoking [‡] | -6.383 | -14.429 – 1.662 | 0.117 |
| Bleeding and PD \geq 4 mm [†] | | | |
| IL-6 | 0.327 | 0.075-0.578 | 0.011 |
| HbA1c | 0.274 | 0.087-0.460 | 0.004 |
| Smoking [‡] | -0.653 | -1.245 – -0.061 | 0.031 |
| Model II; Non-smokers (n = 56) | | | |
| BOP* | | | |
| IL-6 | 1.021 | -2.686 – 4.728 | 0.582 |
| HbA1c | 3.998 | 1.181 – 6.815 | 0.006 |
| Bleeding and PD \geq 4 mm [†] | | | |
| IL-6 | 0.288 | 0.040 – 0.536 | 0.023 |
| HbA1c | 0.218 | 0.011 – 0.425 | 0.039 |

*Linear regression and [†]negative binomial regression models:

Model I; adjusted for age, gender, smoking, HbA1c, serum HDL, plaque and number of sites.

Model II; adjusted for age, gender, HbA1c, BMI, serum HDL, plaque and number of sites.

[‡] Smoking as a categorized variable; non-smokers vs. smokers (reference).

Boldface denotes statistical significance.

Table 4. Adjusted associations between the number of bleeding sites (BOP) and sites with bleeding and PD \geq 4 mm (the outcome variables) and serum IL-6 level after therapy in subjects with BMI \leq 26 kg m⁻² and in non-smokers.

| | B | 95% CI | p-value |
|---|--------------|--------------------|--------------|
| Model III; BMI \leq 26 kg m⁻² (n = 44) | | | |
| BOP | | | |
| IL-6 | 0.287 | -0.069–0.644 | 0.114 |
| HbA1c | 0.078 | -0.159–0.315 | 0.518 |
| Smoking* | -0.210 | -0.968 – 0.548 | 0.588 |
| Bleeding and PD \geq 4 mm | | | |
| IL-6 | 0.550 | 0.016–1.084 | 0.043 |
| HbA1c | -0.052 | -0.454–0.350 | 0.800 |
| Smoking* | 0.308 | -0.911 – 1.527 | 0.621 |
| Model IV; Non-smokers (n = 44) | | | |
| BOP | | | |
| IL-6 | 0.142 | -0.146 – 0.429 | 0.335 |
| HbA1c | 0.015 | -0.214 – 0.244 | 0.896 |
| Bleeding and PD \geq 4 mm | | | |
| IL-6 | 0.402 | -0.023 – 0.827 | 0.064 |
| HbA1c | 0.040 | -0.320 – 0.401 | 0.827 |

Negative binomial regression models:

Model III, adjusted for age, gender, smoking, HbA1c, serum HDL, plaque and number of sites.

Model IV, adjusted for age, gender, HbA1c, BMI, serum HDL, plaque and number of sites.

*Smoking as a categorized variable; non-smokers vs. smokers (reference).

Boldface denotes statistical significance.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 5. Mean serum IL-6 levels (pg/ml) according to the number of sites with bleeding and PD \geq 4 mm after periodontal therapy.

| | BMI \leq 26 kg m ⁻² | | Non-smokers | |
|---|----------------------------------|---------------|-------------|---------------|
| | N | IL-6 pg/ml | N | IL-6 pg/ml |
| All subjects | 44 | 1.6 \pm 1.1 | 44 | 1.6 \pm 1.1 |
| Subjects with | | | | |
| no sites with bleeding and PD \geq 4 mm | 29 | 1.2 \pm 0.6 | 27 | 1.3 \pm 0.6 |
| \geq 1 sites with bleeding and PD \geq 4 mm | 15 | 2.2 \pm 1.6 | 17 | 2.0 \pm 1.5 |
| \geq 2 sites with bleeding and PD \geq 4 mm | 8 | 2.9 \pm 1.9 | 10 | 2.3 \pm 1.8 |
| \geq 3 sites with bleeding and PD \geq 4 mm | 5 | 3.2 \pm 2.3 | 5 | 2.8 \pm 2.4 |

Table 6. Adjusted associations between periodontal healing (the outcome variable) and serum IL-6 level (pg/ml) after therapy using linear regression analysis.

| | B | 95 % CI for B | P-value |
|---|---------------|-------------------------|-------------------|
| IL-6 after therapy (pg/ml) | -0.973 | - 1.599 - -0.348 | 0.003 |
| IL-6 at the baseline (pg/ml) | 0.381 | -0.288 – 1.050 | 0.258 |
| Number of sites with bleeding and PD \geq 4mm at the baseline | 0.951 | 0.922 – 0.980 | < 0.001 |
| Reduction in the number of sites with plaque | 0.028 | 0.002 – 0.055 | 0.039 |
| Smoking | -0.800 | -1.920 – 0.320 | 0.158 |
| BMI | 0.014 | -0.141 – 0.168 | 0.860 |

The outcome variable: **the number of sites with bleeding and PD \geq 4mm after therapy deducted from the number of the sites at the baseline (range -2 - 90).**

Smoking as a categorized variable; non-smokers vs. smokers (reference)

Fig 3.




Fig. 1A. Subject-level changes in serum IL-6 level. A decrease in serum IL-6 level (≥ 0.2 pg/ml) between the baseline and the follow-up examination was observed in 23 subjects (lines on the left) and an increase (≥ 0.2 pg/ml) in 17 subjects (lines on the right). The lines in the middle present subjects with a stable IL-6 level (change < 0.2 pg/ml). Subjects with chronic infections, other than gingivitis or periodontitis, are indicated using dashed lines.

Fig. 1B. Healing of periodontal inflammation indicated as the reduction in the number of sites with bleeding and PD ≥ 4 mm in subjects presenting increased, stable or decreased serum IL-6 level between the baseline and the follow-up examination (see Fig. 1A).

289x171mm (150 x 150 DPI)